“Regulation of neural enzymes”.
US6365573 B1 APR 2, 2002
WO1998014202 A1
AU4639197
EP0929313 A4
CA2267523 A1
Abstract:
This invention relates to the use of the tripeptide Gly-Pro-Glu (GPE) or analogs thereof for the treatment of conditions of the central nervous system (e.g. cerebral vasculitis) in which the amount of the neural enzymes nitric oxide synthetase (NOS) and/or glutamic acid decarboxylase (GAD) is reduced.
Inventor:
Peter D Gluckman
Christopher E. Williams
Jian Guan
Current Assignee:
ENDOCRINZ Ltd
Neuren Pharmaceuticals Ltd
“Regulation of tyrosine hydroxylase”.
US6617311 B1 SEP 9, 2003
WO1999065509 A1
EP1087782 A4
CN1305383 A
CA2334528 A1
Abstract:
This invention relates to methods of regulating the effect of tyrosine hydroxylase (TH). In particular it relates to increasing the effective amount of TH in the central nervous systems (CNS) for the purpose of increasing TH-mediated dopamine production in the treatment of conditions such as Parkinson's disease.
Inventor:
Peter D Gluckman
Christopher E. Williams
Jian Guan
Current Assignee:
ENDOCRINZ Ltd
Neuren Pharmaceuticals Ltd
“Regulation of tyrosine hydroxylase by GPE”.
US6933282 B2 AUG 23, 2005
Abstract:
Embodiments of this invention include methods for increasing the amount of the enzyme tyrosine hydroxylase (TH) in the central nervous system (CNS) of mammals in need of an increase in TH. Methods include the use of the tripeptide, gly-pro-glu (GPE) to increase TH in the CNS. GPE can increase the amount of TH and/or decrease the loss of TH in conditions characterized by a loss of dopamine, such as Parkinson's disease and CNS injury. GPE may act to increase the expression of TH or by inhibiting a decrease in TH expression within the CNS or by inhibiting the loss of TH-containing neurons within the CNS. By increasing the amounts of TH in the CNS, GPE can increase the amount of the neurotransmitter, dopamine, in areas of the CNS responsible for adverse symptoms of neural injury or disease.
Inventor:
Peter D. Gluckman
Jian Guan
Tajrena Alexi
Current Assignee:
ENDOCRINZ Ltd
Neuren Pharmaceuticals Ltd
“Methods to improve neural outcome”.
US6187906 FEB 13, 2001
Abstract:
Disclosed herein is a method for protecting dopaminergic neurons of a mammal against death resulting from Parkinson’s Disease. The method comprises administering a neuroprotective amount of the tripeptide Gly-Pro-Glu.
Inventor:
Peter D. Gluckman
Christopher E. Williams
Jian Guan
Current Assignee:
ENDOCRINZ Ltd
Neuren Pharmaceuticals Ltd
“Effects of Glycyl-2 Methyl Prolyl-L-Glutamate on Neurodegeneration".
US7605177 B2 OCT 20, 2009
Abstract:
This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic and have neuroprotective effects. These agents are useful in treating neurodegeneration and behavioural disorders caused by toxins, traumatic brain injury and autoimmune disorders of the brain, such as multiple sclerosis and in reducing seizures.
Inventor:
Peter David Gluckman
Gregory Brian Thomas
Jian Guan
Michael Dragunow
Ashmit Kumar Anand
Frank Sieg
Margaret Anne Brimble
Current Assignee:
Neuren Pharmaceuticals Ltd
“Cyclic G-2-Allyl-Proline in treatment of Parkinson’s Disease”.
US7776876 B2 AUG 17, 2010
Abstract:
Embodiments of this invention provide methods for therapeutic use of cyclic G-2-Allyl Proline to treat disorders of dopaminergic neurons, including Parkinson's disease. Cyclic G-2Allyl P is neuroprotective and has utility as a therapeutic agent for treatment of diseases and other conditions characterised by degeneration and/or death of dopaminergic neurons and the adverse symptoms of such degeneration and/or death. Such symptoms include loss of cognition and motor function. Compounds are also useful for manufacture of medicaments including tablets, capsules and injectable solutions that are useful for treatment of such conditions.
Inventor:
Margaret Anne Brimble
Jian Guan
Current Assignee:
Neuren Pharmaceuticals Ltd
“Neuroprotective bicyclic compounds and methods for their use”.
US8067425 B2 NOV 29, 2011
WO2005023815 A3
EP1664050 A2
Abstract:
Embodiments of this invention provide novel cyclic compounds structurally related to diketopiperazines and methods for their therapeutic use. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterized by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.
Inventor:
Margaret Anne Brimble
Jian Guan
Frank Sieg
Current Assignee:
Neuren Pharmaceuticals Ltd
PCT Published Patent Application WO2019045575
Filed: August 2018
Inventor: Dr Jian Guan
Assignee: The cGP Lab Ltd, New Zealand
Abstract
Described herein are improvements relating to IGF-1 analysis, adjustment and disease management of non neurological and/or neurological conditions. More specifically, methods relating to the clinical application of cyclic glycine-proline (cGP) biomarker for prediction of risk and recover of non- neurological and/or neurological conditions with IGF-1 dysfunction and the use of a cGP containing organic or plant based material such as concentrated extract of blackcurrant anthocyanins (BCA) for the treatment of same. The methods more accurately measure IGF-1 function in vivo indirectly using cGP and cGP/IGF-1 ratio along with a means to adjust cGP and cGP/IGF-1 ratio (and hence active IGF-1 concentration), and specific treatment methods for individuals with a lower or reduction of cGP level relative to a standard set of baseline data.
PCT Patent Application (PCT/NZ2018/050116)
Filed: December 2022
Inventor: Dr Jian Guan
Assignee: The cGP Lab Ltd, New Zealand